Background: Excess submental fat (SMF), also called a double chin, is an area of concern for men that can be addressed clinically. ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada, Australia, and various European countries) is the first injectable approved for reduction of SMF.
Objective: To share the authors' clinical experience using ATX-101 in men with submental fullness and offer insights regarding how this treatment may be presented to men as an option to improve their submental profile.
Methods: Retrospective review of the authors' medical records for male patients treated with ATX-101.
Results: To allow for fewer ATX-101 treatments, it is recommended that a large surface area be treated at the first session. The positive changes and outcomes achieved with ATX-101 build confidence between the physician and patient, which often leads to male patients seeking other aesthetic treatments to improve their overall appearance.
Conclusion: ATX-101 treatment is often an effective introduction to aesthetic medicine for men.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/DSS.0000000000001306 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Deoxycholic acid (ATX-101) is a drug administered by subcutaneous injection for local fat reduction. However, ATX-101 treatment has been reported to cause marginal mandibular nerve injury with noticeable functional deficits when targeting submental fat. As a cytolytic agent with some selectivity for adipocytes, ATX-101 may damage the lipid-rich myelin surrounding peripheral nerves.
View Article and Find Full Text PDFArticle Synopsis
- Phase 3 trials have shown that ATX-101 is generally safe for reducing submental fat, but real-world experiences report several serious and preventable adverse events related to the procedure.
- The review emphasizes the importance of following proper administration procedures, assessing fat pad thickness, and investigating other causes of fat accumulation to optimize treatment plans for SMF and jowling.
- It also highlights preventive measures to reduce adverse effects, such as avoiding certain injection techniques, ensuring good hygiene, and accurately diagnosing conditions before treatment.
Background: A phase 4, prospective, open-label, multicenter study showed that treatment with deoxycholic acid injections (ATX-10) followed by a hyaluronic acid filler (VYC-20L) is safe and effective for reducing submental fullness and improving jawline definition.
Objective: To quantify changes in the jawline and submental area using 3-dimensional (3D) photogrammetry and conduct an immunohistochemical analysis of submental tissue. Methods: Participants received 1 to 6 ATX-101 treatments (8 weeks apart) followed by VYC-20L (optional touch-up after 14 days).
Degradation Therapy with Collagenase and Deoxycholate.
Facial Plast Surg Clin North Am
November 2023
Union Square Laser Dermatology, 19 Union Square West, 5th Floor, New York, NY 10003, USA.
Deoxycholate (deoxycholic acid) and collagenase are naturally occurring substances whose ability to degrade adipose tissue and collagen respectively has given rise to a variety of therapeutic applications. This article will discuss the indications for the use of deoxycholic acid, primarily its well-established role in the non-surgical reduction of submental fat, with a focus on patient assessment, procedural technique, risks, pitfalls, and key clinical tips. It will also review the indications for collagenase as a degradation therapy, its mechanism of action, and benefits in the management of wound healing, scarring, and adipose tissue modification.
View Article and Find Full Text PDFCONTOUR Australia: Condition of Submental Fullness and Treatment Outcomes with Belkyra Registry.
Plast Reconstr Surg Glob Open
July 2023
Clinical Program Development, AbbVie, Singapore.
Unlabelled: Submental fat (SMF) contributes to an aged or overweight appearance that may negatively impact an individual's psychological well-being. Deoxycholic acid (ATX-101) is an injectable formulation of deoxycholic acid approved to treat SMF. The Condition of Submental Fullness and Treatment Outcomes Registry (CONTOUR) Australia study was designed to understand treatment patterns and outcomes with ATX-101 in Australia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!